Beyin Natriüretik Peptid ve Pediatride Kullanım Alanları

Year 2010, Volume: 8 Issue: 3, 67 - 71, 01.12.2010

A. Barış Akcan , Nihal Oygür

Abstract

Natriüretik peptid ailesi NP , sekiz ve daha fazla birbiriyle ilişkili peptidi içermektedir.Bunlar, 126 aminoasitten oluşan atrial natriüretik peptid ANP prohormonu, 108aminoasitten oluşan brain natriüretik peptid BNP prohormonu, ve 126 aminoasittenoluşan C tipi natriüretik peptid CNP prohormonudur. Natriüretik peptidler sonzamanlarda tanımlanmış olmalarına karşın potansiyel klinik öneme sahiptirler.Natriüretik peptidler, kardiyovasküler hastalıkların tanısı, tedaviye yanıtın ve prognozun değerlendirilmesinde yeni aday markerlardır

Keywords

BNP, kardiyak fonksiyon, natriüretik peptidler

Brain Natriuretic Peptide and Applications in Pediatrics

Abstract

Family of natriuretic peptides NP , consists of eight or more peptides associatedwith each other. These are, atrial natriuretic peptide ANP prohormone consisting of126 amino acids; brain natriuretic peptide BNP prohormone consisting of 108amino acids; C-type natriuretic peptide CNP prohormone consisting of 126 aminoacids. Although recently identified, natriuretic peptides have potential clinical significance. Natriüretic peptide family seems to be a “novel candidate marker”for the assessment of diagnosis, therapeutic response and prognosis in cardiovascular disease

Keywords

BNP, cardiac function, natriuretic peptides

References

• 1. Witthaut R. Science review: natriuretic peptides in critical illness. Crit Care 2004;8:342-9.
• 2. Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 2004;102:223-41.
• 3. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriüretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88.
• 4. Levin ER, Gardner DG, Samson WK. Natriüretic peptides. N Engl J Med 1998;339:321-28.
• 5. Nasser N, Bar-OzB, Nir A. Natriuretic peptides and heart disease in infants and children. J Pediatr 2005;147:248-53.
• 6. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
• 7. Mukoyama M, Nakao K, Hosoda K, Suqa S, Saito Y, Oqawa Y et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
• 8. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP). A new member of the natriuretic peptide family identified in porcine brain. Biochem Biophys Research Commun 1990;168:863-80.
• 9. Naruko T, Ueda M, van der Wal AC, van der Loos CM, Itoh H, Nakao K et al. C-type natriuretic peptide expression in human coronary atherosclerotic lesions. Circulation 1996;94:3103-8.
• 10. Komatsu Y, Nakao K, Itoh H, Suga S, Ogawa Y, Imura H. Vascular natriuretic peptide. Lancet 1992;340:622.
• 11. Maeda K, Tsuramoto T, Wada A, Hisanaga Y, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
• 12. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2006;46:1529-34.
• 13. Maisel AS, Koon J, Krishnaswamy P, Kazeneqra R, Clopton P, Gardetto N et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-74.
• 14. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis 2002;44:293-321.
• 15. Nakamura T, Sakamoto K, Yamano T, Kikkawa M, Zen K, Hikosaka T et al. Increased plasma brain natriuretic peptide level as a quide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:1657-63.
• 16. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic occuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005;91:606-12.
• 17. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children and adolescents. Heart 2003;89:875-8.
• 18. Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004;93:603-7.
• 19. Yoshibayashi M, Kamiya T, Saito Y, Nakao K, Nishioka K, Tema S et al. Plasma brain natriuretic concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol 1995;133:207-9.
• 20. Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002;110:76.
• 21. Mir TS, Laux R, Hellweqe HH, Liedke B, Heinze C, von Buelow H et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003;112:896-9.
• 22. Mir TS, Flato M, Falkenberg J, Haddad M, Budden R, Weil J et al. Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents and young adults: effects of age and gender. Pediatr Cardiol 2006;27:73-7.
• 23. Schwachten L, Herrmann M, Georg T, Schwarz P, Marx N, Lindinger A. Reference values of NT-proBNP serum concentrations in the umblical cord blood and in healthy neonates and children. Z Kardiol 2005;94: 399-404.
• 24. Albers S, Mir TS, Haddad M, Laer S. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparision and interlaboratory variability. Clin Chem Lab Med 2006;44:80-5.
• 25. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L et al. NT-Pro-B-type natriuretic peptide in infants and children: Reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3-8.
• 26. Berger R, Huelsman H, Strecker K, Bojik A, Moser P, Stanek B et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
• 27. Westerlind A, Wahlander H, Lindstedt G, Lundberg PA, Holmgren D. Clinical signs of heart failure are associated with increeased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr 2004;93:340-5.
• 28. Cohen S, Springer C, Avital A, Perles Z, Rein AJJT, Argaman Z et al. Amino-terminal pro-brain-type natriuretic peptide:heart or lung disease in pediatric respiratory distress? Pediatrics 2005;115:1347-50.
• 29. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003;45:249-54.
• 30. Tan LH, Jefferies JL, Liang JF, Denfield SW, Dreyer WJ, Mott AR et al. Concentrations of brain natriuretic peptide in the plasma predicts outcomes of treatment of children with decompensated heart failure admitted to the intensive care unit. Cardiol Young 2007;17:397-406.
• 31. Claudius I, Lan YT, Chang RK, Wetzel GT, Alejos J. Usefulness of B-type natriuretic peptide as a noninvasive screening tool for cardiac allograft pathology in pediatric heart transplant recipients. Am J Cardiol 2003;92:1368-70.
• 32. Takeuchi D, Saji T, Takatsuki S, Fujiwara M. Abnormal tissue Doppler images are associated with elevated plasma brain natriuretic peptide and increased oxidative stres in acute Kawasaki disease. Circ J 2007;7:357-62.
• 33. Gerber IL, Stewart RAH, Legget ME, West TM, French RL, Sutton TM et al. Increased plasma natr›uretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003;107:1884-90.
• 34. Reynolds EW, Ellington JG, Vranicar M, Bada HS. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertansion of the newborn. Pediatrics 2004;114:1297-304.
• 35. Gessler P, Knirsch W, Schmitt B, Rousson V, von Eckardstein A. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in children with congenital heart defects and open-heart surgery. J Pediatr 2006;148: 372-6.
• 36. Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006;27:861-6.
• 37. Fried I, Bar-Oz B, Perles Z, Rein AJ, Zonis Z, Nir A. N-terminal pro-B-type natriuretic peptide levels in acute versus chronic left ventricular dysfunction. J Pediatr 2006;149:28-31.
• 38. Walther FJ, Benders MJ, Leighton JO. Persistent pulmonary hypertansion in premature infants with severe respiratory distress syndrome. Pediatrics 1992;90:899-904.
• 39. Kluckow M, Evans N. High pulmonary blood flow, the duct and pulmonary hemorrhage. J Pediatr 2000;137:68-72.
• 40. Farombi-Oqhuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran JD. N-terminal pro-B-type natriuretic peptide: a measure of significant patent Ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008;93:257-60.